CARsgen Therapeutics Holdings Limited (2171.HK)
| Previous close | 5.700 |
| Open | 5.720 |
| Bid | 5.540 x N/A |
| Ask | 5.560 x N/A |
| Day's range | 5.510 - 5.880 |
| 52-week range | 3.730 - 11.880 |
| Volume | |
| Avg. volume | 1,974,211 |
| Market cap | 3.168B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the initial results from the ongoing first-in-human study of CT071 have been presented at the 29th Annual Congress of the European Hematology Association (EHA).
- PR Newswire
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation a
- PR Newswire
CARsgen Submitted Responses to FDA Observations
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive Actions (CAPAs) plan have been submitted to the U.S. Food and Drug Administration (FDA). This submission is related to the observations identified in the Form 483 issued after the FDA inspection in December 2023 of our clinical manufacturing s
